New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 25, 2012
09:03 EDTSGENSeattle Genetics completes patients enrollment for clinical trial of ADCETRIS
Seattle Genetics and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company, announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS, or brentuximab vedotin, for post-transplant Hodgkin lymphoma, or HL, patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
06:32 EDTSGENAtara Biotherapeutics appoints Eric Dobmeier to board
Atara Biotherapeutics (ATRA) announced that Eric Dobmeier has joined its board. Dobmeier is currently the COO of Seattle Genetics (SGEN).
March 23, 2015
08:22 EDTSGENEditorial on Seattle Genetics AETHERA was positive, says RBC Capital
RBC Capital believes that the Lancet editorial on Seattle Genetics' AETHERA was positive, and the firm expects the drug's label to expand. However, the firm warns that for further upside Seattle Genetics needs one or more programs targeting unmet need with clearly delineated paths to approval. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use